The recombinant human thyroid-stimulating hormone (rhTSH) can be used for differentiated thyroid cancer (DTC) preparation before ¹³¹I therapy, and follow-up. Since its approval by the American Food and Drug Administration (FDA) in 1998, rhTSH has been clinically used in European countries, the United States, and other countries for nearly 30 years. In April 2024, China’s first independently developed rhTSH agent was approved. Based on clinical experience and evidence from domestic and international studies, an expert consensus on the application of rhTSH has been developed following thorough consultations among experts. The consensus offers evidence-based recommendations to guide the appropriate use of rhTSH in clinical practice.

The differentiation between benign and malignant thyroid nodules is pivotal in clinical practice. However, current diagnostic systems face challenges, such as heterogeneity in ultrasound interpretation, the invasiveness of fine-needle aspiration cytology and indeterminate of results. Artificial intelligence (AI) has evolved from traditional machine learning to deep learning, enabling advances in image recognition, feature extraction, and multimodal data integration. Nevertheless, AI applications remain constrained by limitations, including the insufficiency of high-quality annotated data and inadequate cross-center generalizability. Future progress will focus on algorithm refinement, multimodal data fusion, and multicenter clinical validation to enhance model generalizability and diagnostic accuracy.

The differentiation between benign and malignant thyroid nodules is pivotal in clinical practice. However, current diagnostic systems face challenges, such as heterogeneity in ultrasound interpretation, the invasiveness of fine-needle aspiration cytology and indeterminate of results. Artificial intelligence (AI) has evolved from traditional machine learning to deep learning, enabling advances in image recognition, feature extraction, and multimodal data integration. Nevertheless, AI applications remain constrained by limitations, including the insufficiency of high-quality annotated data and inadequate cross-center generalizability. Future progress will focus on algorithm refinement, multimodal data fusion, and multicenter clinical validation to enhance model generalizability and diagnostic accuracy.

Background and Aims:Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer,with a 5-year survival rate of approximately 0％ and a disease-specific mortality rate nearing 100％. Despite the efforts of clinicians and researchers to advance ATC treatment,there is a lack of visualized analysis on trends,leading authors,and research focuses in this field. This study was conducted to explore research hotspots and trends in ATC treatment through visualized analysis of relevant studies.Methods:Relevant literature was retrieved from the Web of Science Core Collection (WoSCC) database,spanning from January 1,2000,to October 31,2023. Visualization analysis was conducted using CiteSpace,VOSviewer,and Pajek software,focusing on indicators such as collaborations among countries/institutions,co-cited journals,co-authorship,co-cited authors,co-cited references and timelines,co-occurring keywords,and citation bursts. Additionally,impact factors (IF) and H-indices were obtained from WoSCC and Scopus databases.Results:A total of 1434 studies were included,involving 7408 authors from 267 countries/regions and 1545 institutions,published in 427 journals. These articles collectively cited 36460 papers authored by 25724 authors from 4032 journals. The analysis revealed that the United States led in publication output (485 articles,33.82％),followed by China (317 articles,22.11％) and Italy (188 articles,13.11％). The University of Texas System was the most prolific institution. The journal Thyroid was the leading contributor in terms of publications and citations. Maria E. Cabanillas was the most prolific author,contributing 30 publications and achieving an H-index of 51 in this field. Co-cited reference analysis identified the study "Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors" by Kebebew Electron,published in Cancer,as the most cited reference,with 241 citations. The timeline of co-cited references highlighted that recent research in the past five years has primarily focused on targeted therapies,novel drug exploration,clinical trials,and guidelines. Keyword clustering analysis identified Akt signaling pathway,targeted therapy,and peptide mRNA nanoparticles as hotspots in ATC research over the past five years. Citation burst analysis showed a shift in research focus from surgery and chemotherapy in earlier years to targeted therapy (2018-2023),BRAF (2020-2023),association guidelines (2020-2023),and radioactive iodine (2020-2023). Additionally,an increasing number of studies have shown significant progress in the application of chimeric antigen receptor T-cell immunotherapy (CAR-T) and nanomaterials in the precision medicine and targeted treatment of thyroid cancer.Conclusion:Research on ATC treatment is on the rise,with the United States maintaining a leading position in this field. Further exploration of molecular biomarkers and specific targets for ATC is essential. Molecular targeted therapies,immunotherapy,CAR-T,and nanomaterials are likely to be key areas of future research.

Background and Aims:Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer,with a 5-year survival rate of approximately 0％ and a disease-specific mortality rate nearing 100％. Despite the efforts of clinicians and researchers to advance ATC treatment,there is a lack of visualized analysis on trends,leading authors,and research focuses in this field. This study was conducted to explore research hotspots and trends in ATC treatment through visualized analysis of relevant studies.Methods:Relevant literature was retrieved from the Web of Science Core Collection (WoSCC) database,spanning from January 1,2000,to October 31,2023. Visualization analysis was conducted using CiteSpace,VOSviewer,and Pajek software,focusing on indicators such as collaborations among countries/institutions,co-cited journals,co-authorship,co-cited authors,co-cited references and timelines,co-occurring keywords,and citation bursts. Additionally,impact factors (IF) and H-indices were obtained from WoSCC and Scopus databases.Results:A total of 1434 studies were included,involving 7408 authors from 267 countries/regions and 1545 institutions,published in 427 journals. These articles collectively cited 36460 papers authored by 25724 authors from 4032 journals. The analysis revealed that the United States led in publication output (485 articles,33.82％),followed by China (317 articles,22.11％) and Italy (188 articles,13.11％). The University of Texas System was the most prolific institution. The journal Thyroid was the leading contributor in terms of publications and citations. Maria E. Cabanillas was the most prolific author,contributing 30 publications and achieving an H-index of 51 in this field. Co-cited reference analysis identified the study "Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors" by Kebebew Electron,published in Cancer,as the most cited reference,with 241 citations. The timeline of co-cited references highlighted that recent research in the past five years has primarily focused on targeted therapies,novel drug exploration,clinical trials,and guidelines. Keyword clustering analysis identified Akt signaling pathway,targeted therapy,and peptide mRNA nanoparticles as hotspots in ATC research over the past five years. Citation burst analysis showed a shift in research focus from surgery and chemotherapy in earlier years to targeted therapy (2018-2023),BRAF (2020-2023),association guidelines (2020-2023),and radioactive iodine (2020-2023). Additionally,an increasing number of studies have shown significant progress in the application of chimeric antigen receptor T-cell immunotherapy (CAR-T) and nanomaterials in the precision medicine and targeted treatment of thyroid cancer.Conclusion:Research on ATC treatment is on the rise,with the United States maintaining a leading position in this field. Further exploration of molecular biomarkers and specific targets for ATC is essential. Molecular targeted therapies,immunotherapy,CAR-T,and nanomaterials are likely to be key areas of future research.

Objective:To investigate the clinical risk factors of large volume lymph node metastasis (LV-LNM) in the central region of papillary thyroid cancer (PTC) .Methods:The clinical data of 1367 PTC patients admitted to the Department of Oncological Surgery, Hangzhou First People’s Hospital, Affiliated to Zhejiang University School of Medicine from Jan. 2016 to Jan. 2019 were retrospectively analyzed. There were 310 males and 1057 females. A total of 1644 cases of central region were included in the study.According to the number of lymph node metastasis in the central area, they were classified into small-volume lymph node metastasis (SV-LNM) group and LV-LNM group.71 cases of LV-LNM, 1573 cases of SV-LNM.The correlation between CLNM and LV-LNM and various clinicopathological features such as the sex, age, tumor size and so on of PTC patients was analyzed by chi-square test and Logistic regression analysis.Results:The proportion of CLNM in the affected side was 35.28% (580/1 644) , and the incidence of LV-LNM in the central area of the affected side was 4.32% (71/1644) . Univariate analysis showed that the LV-LNM in the central region of the affected side was closely correlated with gender, age, bilateral lesions, multiple lesions, size of lesions, membranous invasion and lateral cervical lymph node metastasis on the affected side were closely related ( P<0.05) . Multivariate regression analysis showed that male (OR=2.115, P=0.006) , age < 38 years old (OR=0.586, P=0.004) , multiple lesions on the affected side (OR=2.837, P=0.004) , lesions >7mm on the affected side (OR=1.762, P=0.002) and cervical lymph node metastasis on the affected side (OR=7.023, P<0.001) were independent predictors of LV-LNM in the central region of the affected side ( P<0.001) . The receiver operating characteristic curve (ROC) , sensitivity and specificity of LV-LNM predicted by the model were 0.839, 81.69% and 78.39%. The incidence of ipsilateral cervical lymph node metastasis in the affected central region of LV-LNM was 11.57 times higher than that of SV-LNM. Conclusion:PTC with male, age < 38 years old, multiple lesions on the affected side, lesion >7 mm and lateral cervical lymph node metastasis are prone to LV-LNM in the affected central region.

Objective To investigate the diagnostic value of lymph node size and distribution in ipsilateral central lymph node metastasis (ICLNM) of single papillary thyroid carcinoma (PTC) in CT examination.Method The CT data of 278 single PTC with diameter ＞ 1.0 cm confirmed by operation and pathology were retrospectively analyzed.According to the ipsilateral central lymph node diameter,these cases were divided into ＜ 0.2 cm group,0.2-0.4 cm group and ≥0.4 cm group,and the distribution difference of ICLNM positive and negative between the three groups were analyzed.Then according to the lymph node distribution,0.2 to 0.4 cm group were divided into turbidity group (≥ 3) and non-turbidity group (1-2),and ≥0.4 cm group were divided into cluster group (≥ 3) and non-cluster group (1-2).The differences betweeen turbidity group and non-turbidity group,cluster group and non-cluster group were analyzed.Results In 278 PTC,the proportion of ICLNM positive and negative was 65.8％(183/278) and 34.2％(95/278),respectively.ICLNM positive in ＜0.2 cm group,0.2-0.4 cm group and ≥0.4 cm group accounted for 37.3％ (31/83),68％ (66/97) and 87.8％ (86/98),respectively.x2 value and P value in between groups and within groups were 51.082 and 0,16.956 and 0,49.955 and 0,11.022 and 0.001,respectively.ICLNM positive in turbidity group and non-turbidity group accounted for 74.0％ (57/77) and 45％ (9/20),respectively.x2 value and P value were 6.151 and 0.013,respectively.ICLNM positive in cluster group and and non-cluster group accounted for 92.6％(50/54) and 82％(36/44),respectively.x2 value and P value were 2.619 and 0.106,respectively.Conclusions Among CT examination of patients with PTC,with the increase of the diameter and number of lymph nodes in central group,the positive proportion of ICLNM positive increases.For the 0.2-0.4 cm group,the turbidity phenomenon suggests that the possibility of metastasis is greater.The accurate identification of these signs can help surgeons take a more thorough surgical treatment and have great significance to reduce postoperative recurrence.

Objective To investigate the relationship between Hashimoto thyroiditis (HT) and thyroid papillary carcinoma (PTC) by analyzing the expression of BRAF V600E mutation and (N-,H-,K-) RAS codons 12,13 and 61 mutants in cases of multifocal PTC with HT.Methods 80 tumor samples in 37 multifocal PTC with HT cases,were analyzed for the genotypic changes of BRAF V600E,as well as the (N-,H-,K-)RAS codons 12,13 and 61 mutants by DNA sequencing assay and amplification refractory mutation system (ARMS).Results BRAF V600E mutation was detected in 51 samples and RAS gene mutations was found in 3 samples (N-RAS codon 61 mutant in 2 samples and H-RAS codon 61 mutant in 1 sample).Different clonal origin was present in 20 cases of multifocal PTC with HT (54.1％,20/37).There was no statistical significance (P ＞ 0.05) in the incidence of the difference in the origin of tumor cells,compared with the results (61.7％,37/60) of multifocal PTC without HT in the related literature.Conclusion In more than half of multifocal PTC with HT cases,the tumor cells originate from different clones.Our results do not support the opinion that HT predisposes patients to develop PTC,because HT does not have a significant effect on expression of BRAF and RAS gene mutation in PTC,accordingly HT is more likely to be a part of the host tumor immune response system.

Objective To analyze long noncoding RNAs (lncRNAs) expression profiles in papillary thyroid carcinoma (PTC) with Hashimoto's thyroiditis (PTC-HT,group A) and PTC only (PTC,group B).Methods 55 cases of thyroid species were collected.High-throughput microarray lncRNh was used to detect the expression difference of lncRNAs between group A and group B.Real-time quantitative PCR (QRT-PCR) was used to verify.Results 1031 lncRNAs and 1338 mRNAs were detected abnormally expressed in tissue samples of group A compared to B.GO and Pathway analysis of mRNAs suggested some biological processes changed obviously,such as immune system and immune reaction.QRT-PCR showed that the expression of uc002stn.1,ENST00000452578 and uc002sti.1 in group A and group B was significantly different.Conclusion IncRNAs expression was significantly different in PTC with or without HT,which may play important roles in the pathogenesis of PTC with HT.

Objective To investigate the diagnostic value of computed tomography (CT) histogram analysis for thyroid malignant solitary coarse calcification nodules (MSCN).Methods A total of 89 thyroid solitary coarse calcification nodules (coarse calcification ≥5 mm,no definite soft tissue around calcification) confirmed either by surgery or histopathological examination in 86 patients enrolled in this study from Jan.2009 to Dec.2015 were evaluated,including 33 MSCN from 32 patients and 56 benign solitary coarse calcification nodules (BSCN) from 56 patients.Overall,27 cut-off values were calculated by N (4 ≤ N ≤ 30) times of 50 Hounsfield units (HU) in the range of 200 HU to 1500 HU,and each cut-off value and the differences in the corresponding area percentages in the CT histogram were recorded for MSCN and BSCN.The optimal cut-off value and the corresponding area percentage were established by receiver operating characteristic (ROC) curve analysis.Results In the 24 groups with an ROC area under the curve (AUC) of more than 0.7,at a cut-off value of 1150 HU and at an area percentage of no less than 98.4％,the ROC AUC reached a maximum of 0.86,and the accuracy,sensitivity,and specificity were 70.8％,93.9％,and 57.1％,respectively.At a cut-off value of 450 HU and at an area percentage of no less than 46.3％,the accuracy,sensitivity,and specificity were 76.4％,48.5％,and 92.9％,respectively.At a cut-off value of 550 HU and at an area percentage of no less than 81.5％,the accuracy,sensitivity,and specificity were 75.3％,33.3％,and 100％,respectively.Conclusions In comparison with the cut-off value of 1150 HU with an area percentage of no less than 98.4％,the sensitivities for the cut-off value of 450 HU with an area percentage of no less than 46.3％ and for the cut-off value of 550 HU with an area percentage of no less than 81.5％ were lower;however,the specificities increased significantly,providing an important basis for reducing the misdiagnosis of MSCN.